LongBio Pharma

LongBio Pharma (Suzhou/Shanghai, founded 2020) is a Chinese clinical-stage biopharmaceutical company focused on the in-house discovery and development of innovative antibody and fusion-protein therapeutics for allergic, autoimmune, and complement-mediated diseases. Its lead programs include the anti-IgE antibody LP-003 for chronic spontaneous urticaria and asthma. Co-founded by Dr. Bill Nai-chau Sun (co-founder of Tanox and co-inventor of Omalizumab/Xolair), LongBio raised a Series B2 round led by Qiming Venture Partners and listed on the Hong Kong Stock Exchange (01779.HK) in June 2026. It is a pharmaceutical drug developer with no public developer or API surface; this profile was surfaced as a Qiming portfolio company and completed an enrichment pass.

LongBio Pharma is profiled on the APIs.io network. Tagged areas include Company, Pharmaceuticals, Biotechnology, Healthcare, and Drug Discovery.

🌐 Visit website 📡 Source on GitHub

5.7/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-07-27 · rubric v0.5

0 APIs

CompanyPharmaceuticalsBiotechnologyHealthcareDrug DiscoveryAntibodiesAutoimmuneAllergy

Kin Score

Kin Score How this is scored →
scored 2026-07-27 · rubric v0.5

Composite quality — 5.7/100 · minimal

Contract Quality 0.0 / 25

Developer Ergonomics 0.0 / 20

Commercial Clarity 0.0 / 20

Operational Transparency 0.0 / 13

Governance 0.0 / 12

Discoverability 6.8 / 10

Agent readiness — 0/100 · human only

Machine-Readable Contract 0 / 18

Agentic Access Contract 0 / 15

MCP Server 0 / 12

Machine-Readable Auth 0 / 10

Idempotency 0 / 9

Stable Error Semantics 0 / 8

Request/Response Examples 0 / 7

Rate-Limit Signaling 0 / 7

Typed Event Surface 0 / 6

Agent Skills 0 / 5

Well-Known Catalog 0 / 4

Consent & Bot Identity 0 / 3

Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/longbio: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Resources

Company 2

The organization behind the API

Website

Website

LinkedIn

Source (apis.yml)

aid: longbio
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/longbio.png
name: LongBio Pharma
description: LongBio Pharma (Suzhou/Shanghai, founded 2020) is a Chinese clinical-stage biopharmaceutical company focused
  on the in-house discovery and development of innovative antibody and fusion-protein therapeutics for allergic, autoimmune,
  and complement-mediated diseases. Its lead programs include the anti-IgE antibody LP-003 for chronic spontaneous urticaria
  and asthma. Co-founded by Dr. Bill Nai-chau Sun (co-founder of Tanox and co-inventor of Omalizumab/Xolair), LongBio raised
  a Series B2 round led by Qiming Venture Partners and listed on the Hong Kong Stock Exchange (01779.HK) in June 2026. It
  is a pharmaceutical drug developer with no public developer or API surface; this profile was surfaced as a Qiming portfolio
  company and completed an enrichment pass.
url: https://raw.githubusercontent.com/api-evangelist/longbio/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- qiming
x-tier: stub
x-tier-reason: portfolio-lead
specificationVersion: '0.20'
created: '2026-07-17'
modified: '2026-07-20'
tags:
- Company
- Pharmaceuticals
- Biotechnology
- Healthcare
- Drug Discovery
- Antibodies
- Autoimmune
- Allergy
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: Website
  url: https://www.longbio.com
- type: LinkedIn
  url: https://www.linkedin.com/company/longbio
x-enrichment:
  date: '2026-07-20'
  status: nochange
  artifacts_added: 0
  pass: local-v1